Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prestige to buy GSK OTC brands for $660m
GSK’s portfolio of 17 OTC brands comprises pain relievers BC, Goody’s and Ecotrin; gastrointestinal brands Beano, Gaviscon, Phazyme, Tagamet, and Fiber Choice; and Sominex sleep aids. According to
GSK’s portfolio of 17 OTC brands comprises pain relievers BC, Goody’s and Ecotrin; gastrointestinal brands Beano, Gaviscon, Phazyme, Tagamet, and Fiber Choice; and Sominex sleep aids. According to
The collaboration is focused on developing potential drug candidates to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis. In March 2011,
As per the previous agreement, UniPharma had the exclusive right to distribute Radient’s cancer test in Taiwan. The expanded distribution agreement includes Singapore, Hong Kong and Macau. As
Under the terms of the collaboration, Anika will receive an initial payment of $2.5m besides being entitled to receive additional payments from after the launch of the product
Gevokizumab, a humanized monoclonal antibody, acts by suppressing the activation of interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, thereby modulating the cellular signaling events that produce inflammation. The
The initiative is believed to enable Novocol to diversify and develop new infection control products thereby increasing its competitiveness globally. Novocol is investing over $54m in the project
The milestone payment was made under the terms of the agreement between Purdue and Transcept for the commercialization of Intermezzo in the US. Intermezzo (zolpidem tartrate) sublingual tablet
BioSystem Development’s AssayMAP platform, based on disposable microchromatography cartridges, enables for the first time, automation of complex, multi-step sample preparation workflows. They include protein purification, characterization and analysis
JX-594 is a proprietary, engineered oncolytic virus that will selectively target and destroy cancer cells by degrading cancer cells through viral replication, blocking the blood supply to tumors
According to the company, Scenesse is the first photoprotective drug developed as a prophylactic treatment for phototoxicity experienced by patients with EPP, a rare light intolerance disease. CUV029,